CN1519021A - Stable erythropoietin of recombined human red blood cell - Google Patents
Stable erythropoietin of recombined human red blood cell Download PDFInfo
- Publication number
- CN1519021A CN1519021A CNA031006531A CN03100653A CN1519021A CN 1519021 A CN1519021 A CN 1519021A CN A031006531 A CNA031006531 A CN A031006531A CN 03100653 A CN03100653 A CN 03100653A CN 1519021 A CN1519021 A CN 1519021A
- Authority
- CN
- China
- Prior art keywords
- preparation
- rhuepo
- erythropoietin
- mannitol
- buffer solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
A stable recombinant human guanophore poietin (rHuEPO) in the form of injection for treating renal anemia and the anemia caused by surgical operation and chemicotherapy contains rHuEPO, mannitol as protein protector, sodium chloride as the isotonic agent of buffer liquid and water. Its advantages are high safety and no by-effect.
Description
Technical field
The present invention relates to a kind of genetic engineering recombiant protein (recombinant human erythropoietin rHuEPO) preparation that does not contain the human albumin and preparation method thereof.
Background technology
(Erythropoietin is a kind of glycoprotein EPO) to erythropoietin, and molecular weight is about 30～39KD.Difference according to its sugared type structure can be divided into two kinds of α, β.Its physiological action is to stimulate hemoglobin or erythrocytic formation in the bone marrow, is mainly generated and entered bone marrow by circulation blood by kidney to play a role.Recombinant human erythropoietin rHuEPO has structure and the physiological action identical with natural erythropoietin EPO, has been widely used in the anemia that erythrocyte is mobilized, chemotherapy of tumors causes of renal anemia, surgery peri-operation period etc. clinically.
EPO working concentration in vivo is very low, and human body is very responsive for the minor variations of EPO level, must be based upon an exogenous hormone that can guarantee this trace accurately on the basis of the preparation of administration so depend on the treatment of rHuEPO.But known rHuEPO is in aqueous solution and unstable (seeing patent US 4,806,524), so the stability that adds one or more protective agents increase rHuEPO in rHuEPO solution prevents that on its inwall that is attracted to container be necessary.
Known in gene recombinant protein quasi drugs preparation, the human albumin is a kind of common and effective stabilizer (seeing patent US 4,703,008).But, inevitably exist potential haematogenous pollution problem (as infecting hepatitis virus, HIV (human immunodeficiency virus) etc.) because the human albumin is a blood products.Therefore research worker is by having adopted the kinds of protect agent to replace the human albumin to the research of rHuEPO.For example patent US 4,879, the lecithin of mentioning in 272, Gentran 40, methylcellulose, Polyethylene Glycol etc.But patent US 4,992, and 419 studies show that with such reagent and can not reach long term stabilization, and promptly the effectiveness of rHuEPO reduces greatly in mouse experiment, and can cause immunogenic response when injecting these reagent; In addition, from patent US 4,992,419 and patent US 5,376,632, the stabilizing agent that some is applicable to lyophilizing rHuEPO preparation be can recognize, carbamide, each seed amino acid and cyclodextrin comprised.But adopt freeze-dried formulation inconvenience for ejection preparation, increased the chance of dissolved step and operation and pollution impurity.In addition,, not only increased cost, and made quality be not easy to control, the stability between the different batches is affected owing to increased freeze dried operation in process of production.
Therefore, problem is to locate a kind of be easy to mix, the rHuEPO preparation that can stablize storage, can guarantee its accurate administration, can prevent that again it is adsorbed on peace bottle and the injector wall; Can not only keep its secular biological activity and stability, and production technology is simple, production cost is low.
Summary of the invention
The purpose of this invention is to provide a kind of genetic engineering recombiant protein (recombinant human erythropoietin, rHuEPO) preparation and preparation method thereof that mix, stable storage that does not contain the human albumin.Repeatedly testing discovery according to us and add mannitol can prevent effectively that rHuEPO is adsorbed in rHuEPO solution, increase the stability of rHuEPO and active, is protective agent so the present invention adopts mannitol, and production technology is simple, and is safe and reliable.
The object of the present invention is achieved like this: the invention provides a kind of recombinant erythropoietin liquor preparation that is mainly used in the treatment renal anemia, said preparation contains protective agent mannitol.Pharmaceutical solutions of the present invention is the aqueous solution for injection agent, can contain following component:
(1) is recombinant human erythropoietin's protein 10 0～20000 iu/milliliter of active component;
Buffer 5～the 100mM that (2) can mix on the physiology, pH4.0～8.5;
(3) isoosmotic adjusting agent sodium chloride 0.05～1.0%;
(4) be protective agent mannitol 1.0～20.0%;
(5) water.
The buffer that mixes on the selected physiology of the present invention can adopt citrate buffer or adopt phosphate buffer or adopt glycine buffer or adopt acetate buffer or carbonate buffer solution, working concentration is 5～100mM, pH4.0～8.5.Be used for the requirement of required pH value of stable prod and drug solubility.
The selected citrate buffer of the present invention can also be got rid of the proteinic destruction of trace heavy metal ion pair in the injection as the chela mediating recipe except keeping the suitable pH value of rHuEPO, the working concentration scope is 5～100mM.
Sodium chloride of the present invention has guaranteed the osmotic pressure that is consistent in injection and the body, and concentration is 0.05～1.0%.
The present invention adopts mannitol to cook protective agent, stops proteinic condensing to increase proteinic dissolubility, and concentration is between 1.0～20.0%.
Also can contain metal ion chela mediating recipe in the preparation of the present invention as the disodium salt disodium, reaction has remarkable catalytic action to trace metal ion to autoxidation, can add the generation that metal ion chela mediating recipe suppresses the autoxidation reaction.
Also can contain the L-histidine hydrochloride in the preparation of the present invention, there are certain biocompatibility in it and protein, and protein is had the certain protection effect, simultaneously, as antioxidant, can reduce the oxidative degradation of rHuEPO in the long preservation process.
Above-described percentage composition is a weight percentage.
Characteristics of the present invention are: use method provided by the invention, can produce a kind of do not contain the human albumin mix, storage period is long and the genetic engineering recombinant human erythropoietin rHuEPO of stable storage.The present invention also has characteristics such as preparation method is simple, production cost is low, effect is good.
The specific embodiment
Below will the present invention will be further described by embodiment, but following example only is the present invention's example wherein, the interest field of not representing the present invention and being limited.
Embodiment 1.
The rHuEPO of 1000 200 units of preparation:
Component content
Citrate buffer solution 20mM
20% mannitol 4%
Sodium chloride 0.585%
Recombinant human erythropoietin's 200 ius
Surplus is a water.
Measure 700 milliliters of ultra-pure waters, accurately take by weighing citrate dihydrate trisodium 5.80 grams, citric acid monohydrate 0.062 gram, sodium chloride 5.85 grams then, be dissolved in 700 milliliters of ultra-pure waters, fully after the dissolving, make A liquid, keep solution temperature, measure the solution pH value between 6.9～7.0 at 20～25 ℃.
Accurately measure 200 milliliter of 20% mannitol and be dissolved in the A liquid, fully mixing keeps solution temperature at 20～25 ℃.Add 2 * 10 in the mixed solution
5The rHuEPO albumen of unit is settled to 1000 milliliters with ultra-pure water.The finished product preparation of preparation rHuEPO.
Finished product preparation is aseptically filled in the container of sterilization.Packing then, every bottle adds 1 milliliter of finished product preparation, and the nitrogen that passes to aseptic filtration in whole process for preparation rolls the rHuEPO injection that lid is made 200 units at last to get rid of air in the bottle.
Embodiment 2.
The rHuEPO of 1000 1000 units of preparation:
Component content
Phosphate buffer 1 0mM
20% mannitol 2%
Sodium chloride 0.584%
Recombinant human erythropoietin's 1000 ius
Surplus is a water.
Measure 700 milliliters of ultra-pure waters, accurately take by weighing sodium hydrogen phosphate 2.51 grams, sodium dihydrogen phosphate 0.47 gram, sodium chloride 5.84 grams, be dissolved in 700 milliliters of ultra-pure waters, fully after the dissolving, make A liquid, keep solution temperature, measure the solution pH value between 6.9～7.0 at 20～25 ℃.
Accurately measure 100 milliliter of 20% mannitol and be dissolved in the A liquid, fully mixing keeps solution temperature at 20～25 ℃.Add 1 * 10 in the mixed solution
6The rHuEPO albumen of unit is settled to 1000 milliliters with ultra-pure water.The finished product preparation of preparation rHuEPO.
Finished product preparation is aseptically filled in the container of sterilization.Packing then, every bottle adds 1 milliliter of finished product preparation, and the nitrogen that passes to aseptic filtration in whole process for preparation rolls the rHuEPO injection that lid is made 1000 units at last to get rid of air in the bottle.
Embodiment 3.
The rHuEPO of 1000 4000 units of preparation:
Component content
Glycine buffer 50mM
20% mannitol 8%
Sodium chloride 0.9%
Disodium salt disodium 0.01%
Recombinant human erythropoietin's 4000 ius
Surplus is a water.
Measure 500 milliliters of ultra-pure waters, accurately take by weighing glycine 3.75 grams, sodium chloride 9.0 grams, be dissolved in 500 milliliters of ultra-pure waters, fully after the dissolving, make A liquid, keep solution temperature, measure the solution pH value between 6.9～7.0 at 20～25 ℃.
Take by weighing disodium salt disodium 0.10 gram, add in the A liquid, fully mixed dissolution keeps solution temperature at 20～25 ℃, and this is a B liquid.
Accurately measure 400 milliliter of 20% mannitol and be dissolved in the B liquid, fully mixing keeps solution temperature at 20～25 ℃.Add 4 * 10 in the mixed solution
6The rHuEPO albumen of unit is settled to 1000 milliliters with ultra-pure water.The finished product preparation of preparation rHuEPO.
Finished product preparation is aseptically filled in the container of sterilization.Packing then, every bottle adds 1 milliliter of finished product preparation, and the nitrogen that passes to aseptic filtration in whole process for preparation rolls the rHuEPO injection that lid is made 4000 units at last to get rid of air in the bottle.
Embodiment 4.
The rHuEPO of 1000 8000 units of preparation:
Component content
Phosphate buffer 1 0mM
20% mannitol 4%
Sodium chloride 0.584%
L-histidine hydrochloride 0.1%
Recombinant human erythropoietin's 8000 ius
Surplus is a water.
Measure 700 milliliters of ultra-pure waters, accurately take by weighing sodium hydrogen phosphate 2.51 grams, sodium dihydrogen phosphate 0.47 gram, sodium chloride 5.84 grams, be dissolved in 700 milliliters of ultra-pure waters, fully after the dissolving, make A liquid, keep solution temperature, measure the solution pH value between 6.9～7.0 at 20～25 ℃.
Take by weighing L-histidine hydrochloride 1 gram, add in the A liquid, abundant mixed dissolution, this is a B liquid.
Accurately measure 200 milliliter of 20% mannitol and be dissolved in the B liquid, fully mixing keeps solution temperature at 20～25 ℃.Add 8 * 10 in the mixed solution
6The rHuEPO albumen of unit is settled to 1000 milliliters with ultra-pure water.The finished product preparation of preparation rHuEPO.
Finished product preparation is aseptically filled in the container of sterilization.Packing then, every bottle adds 1 milliliter of finished product preparation, and the nitrogen that passes to aseptic filtration in whole process for preparation rolls the rHuEPO injection that lid is made 8000 units at last to get rid of air in the bottle.
Embodiment 5.
The rHuEPO of 1000 10000 units of preparation:
Component content
Citrate buffer solution 20mM
20% mannitol 2%
Sodium chloride 0.585%
L-histidine hydrochloride 0.1%
Disodium salt disodium 0.01%
Recombinant human erythropoietin's 10000 ius
Surplus is a water.
Measure 700 milliliters of ultra-pure waters, accurately take by weighing citrate dihydrate trisodium 5.80 grams, citric acid monohydrate 0.062 gram, sodium chloride 5.85 grams, be dissolved in 700 milliliters of ultra-pure waters, fully after the dissolving, make A liquid, keep solution temperature, measure the solution pH value between 6.9～7.0 at 20～25 ℃.
Accurately take by weighing disodium salt disodium 0.1 gram, add in the A liquid, abundant mixed dissolution, this is a B liquid.
Accurately take by weighing L-histidine hydrochloride 1 gram, add in the B liquid, abundant mixed dissolution, this is a C liquid.
Accurately measure 100 milliliter of 20% mannitol and be dissolved in the C liquid, fully mixing keeps solution temperature at 20～25 ℃.Add 1 * 10 in the mixed solution
7The rHuEPO albumen of unit is settled to 1000 milliliters with ultra-pure water.The finished product preparation of preparation rHuEPO.
Finished product preparation is aseptically filled in the container of sterilization.Packing then, every bottle adds 1 milliliter of finished product preparation, and the nitrogen that passes to aseptic filtration in whole process for preparation rolls the rHuEPO injection that lid is made 10000 units at last to get rid of air in the bottle.
In order to measure the bin stability of the different finished product preparation of preparing, carried out the preparation stored controlled trial.Adopt recombinant human erythropoietin (rHuEPO) semi-finished product of same batch (to meet " Chinese biological goods vertification regulation ", purity is greater than 98%), carry out the test preparation of different size preparation, wherein matched group is made into the preparation that contains 0.25% human albumin.Be divided into two groups according to different temperature conditions: 37 ℃ of groups and 4 ℃ of groups, the observation period was respectively 3 months and 2 years, regularly detected outward appearance, pH value, purity and the activity in vivo of rHuEPO in the preparation.The result shows, under 37 ℃ of conditions, included human albumin's matched group in three months all to significantly decrease with the activity that does not contain human albumin's test group, but both do not have evident difference.Under 4 ℃ of conditions, including human albumin's matched group in 2 years does not all have decline with the activity that does not contain human albumin's test group, and both do not have evident difference (the results are shown in following table).
Preserve trimestral experimental result for 37 ℃
| Group | PH value | Purity | Active (IU/ml) | Outward appearance |
| Embodiment 1 | ????6.92 | ????96.4％ | ????137 | Qualified |
| Contrast | ????6.98 | ????96.8％ | ????152 | |
| Embodiment 2 | ????7.00 | ????95.6％ | ????640 | |
| Contrast | ????6.94 | ????96.1％ | ????634 | |
| Embodiment 3 | ????7.01 | ????96.0％ | ????2418 | |
| Contrast | ????6.98 | ????96.4％ | ????2720 | |
| Embodiment 4 | ????6.95 | ????95.0％ | ????4482 | |
| Contrast | ????7.00 | ????96.2％ | ????4640 | |
| Embodiment 5 | ????6.90 | ????95.5％ | ????5506 | |
| Contrast | ????6.92 | ????96.0％ | ????5524 |
4 ℃ of experimental results of preserving 2 years
| Group | PH value | Purity | Active (IU/ml) | Outward appearance |
| Embodiment 1 | ????7.00 | ????98.4％ | ????212 | Qualified |
| Contrast | ????6.96 | ????98.8％ | ????208 | |
| Embodiment 2 | ????6.94 | ????99.2％ | ????986 | |
| Contrast | ????6.98 | ????99.0％ | ????1020 | |
| Embodiment 3 | ????6.97 | ????99.0％ | ????3890 | |
| Contrast | ????7.00 | ????99.2％ | ????3865 | |
| Embodiment 4 | ????6.92 | ????98.5％ | ????7921 | |
| Contrast | ????6.89 | ????99.2％ | ????7963 | |
| Embodiment 5 | ????6.95 | ????98.9％ | ????10040 | |
| Contrast | ????6.97 | ????99.0％ | ????10120 |
The result shows, use method provided by the invention, produce a kind of genetic engineering recombinant human erythropoietin rHuEPO that mix, stable storage that does not contain the human albumin, can keep stable 4 ℃ of activity of preserving 2 years recombinant human erythropoietin rHuEPO.
Claims (10)
1, a kind of erythropoietin liquor preparation is characterized in that, contains protective agent mannitol in the said preparation.
2, the preparation of claim 1, contain following component:
(1) erythropoietin, 100～20000 iu/milliliters;
Buffer solution 5～the 100mM that (2) can mix on the physiology, pH4.0～8.5;
(3) sodium chloride, 0.05～1.0%;
(4) mannitol, 1.0～20.0%;
(5) water.
3, the preparation of claim 2, buffer solution wherein is selected from, phosphate buffered solution, citric acid solution, glycine buffer solution, carbonate buffer solution, acetate buffer solution.
4, the preparation of claim 2 is characterized in that, also contains metal ion chela mediating recipe in the preparation,
5, the preparation of claim 4, described metal ion chela mediating recipe is the disodium salt disodium, content is 0.001～0.2%.
6, the preparation of claim 2 is characterized in that, also contains the L-histidine hydrochloride in the preparation, and content is 0.01～1.5 ‰.
7, the preparation of claim 2, erythropoietin wherein are that gene recombinaton erythropoietin content is 200～10000 iu/milliliters.
8, the preparation method of the preparation of claim 2 is characterized in that, mannitol, erythropoietin and the buffer solution that contains sodium chloride are mixed.
9, the preparation of claim 2 is injections.
10, the application of the preparation of claim 2 in the medicine that the preparation promoting erythrocyte generates.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 03100653 CN1247257C (en) | 2003-01-20 | 2003-01-20 | Stable erythropoietin of recombined human red blood cell |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 03100653 CN1247257C (en) | 2003-01-20 | 2003-01-20 | Stable erythropoietin of recombined human red blood cell |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1519021A true CN1519021A (en) | 2004-08-11 |
| CN1247257C CN1247257C (en) | 2006-03-29 |
Family
ID=34281254
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 03100653 Expired - Lifetime CN1247257C (en) | 2003-01-20 | 2003-01-20 | Stable erythropoietin of recombined human red blood cell |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1247257C (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103041370A (en) * | 2013-01-11 | 2013-04-17 | 罗诚 | Drug composition containing recombinant human erythropoietin and preparation method of drug composition |
-
2003
- 2003-01-20 CN CN 03100653 patent/CN1247257C/en not_active Expired - Lifetime
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103041370A (en) * | 2013-01-11 | 2013-04-17 | 罗诚 | Drug composition containing recombinant human erythropoietin and preparation method of drug composition |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1247257C (en) | 2006-03-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1027224C (en) | Stabilised human protein preparations | |
| CN1130223C (en) | A pharmaceutical formulation containing growth hormone, an amino acid and a non-ionic detergent | |
| US20190010149A1 (en) | Sustained-release formulation for injection | |
| CN1246039C (en) | Moxilfloxacin formulation containing common salt | |
| CN1802171A (en) | Stable, aqueous solution of human erythropoietin, not containing serum albumin | |
| JP2015535238A (en) | Stable pharmaceutical composition of pegylated interferon α-2b | |
| CN112402371B (en) | Rudesiwei injection and preparation method thereof | |
| CN1247257C (en) | Stable erythropoietin of recombined human red blood cell | |
| CN106668867A (en) | Mumps vaccine freeze-drying protective additive free of gelatin and human albumin | |
| CN1371284A (en) | Multi-dose erythropoietin formulations | |
| KR20030016426A (en) | FREEZE-DRIED PREPARATION OF N-[o-(p-PIVALOYLOXYBENZENESULFONYLAMINO)BENZOYL]GLYCINE MONOSODIUM SALT TETRAHYDRATE AND PROCESS FOR PRODUCING THE SAME | |
| CN104888196A (en) | Stable interferon alpha multi-dose pen injection | |
| CN102283804A (en) | Meglumine adenosine cyclophosphate injection and preparation method thereof | |
| US11077193B2 (en) | Nerve growth factor composition and powder injection | |
| CN1341591A (en) | Solution of tetrahydrate N-[ortho-(para-trimethyl acetoxyl benzenesulfonamide) benzoyl] glycine monosodium salt and its medicine | |
| CN1318087C (en) | Removing albumin nerve growth factor agent | |
| CN100346782C (en) | Vitamin C composition containing amino acids | |
| CN1839842A (en) | Pharmaceutical composition containing levosimendan or its pharmaceutically acceptable salt as active ingredient | |
| CN1193790C (en) | Thymosin composition injection and its prepn | |
| CN101062406A (en) | Reeombinnt human granulocyte colony stimulating factor microemulsion | |
| CN1857720A (en) | Freeze dried human cell fibronection powder and its preparing method | |
| WO2017114214A1 (en) | Composition, applications thereof, and stabilizer comprising composition | |
| CN115702880B (en) | Recombinant insulin glargine injection and preparation process thereof | |
| CN108272755B (en) | A kind of hydrochloride for injection mycophenolate mofetil lyophilized preparation and preparation method thereof | |
| CN104958302A (en) | Cefoperazone sodium tazobactam sodium medicine composition for injection and preparing process of cefoperazone sodium tazobactam sodium medicine composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C56 | Change in the name or address of the patentee |
Owner name: SHENYANG SANSHENG PHARMACEUTICAL CO. Free format text: FORMER NAME OR ADDRESS: SANSHENG PHARMACY CO., LTD., SHENYANG CITY |
|
| CP01 | Change in the name or title of a patent holder |
Address after: 1 No. 3, ten, road 110141, Shenyang economic and Technological Development Zone, Liaoning, China Patentee after: SHENYANG SUNSHINE PHARMACEUTICAL Co.,Ltd. Address before: 1 No. 3, ten, road 110141, Shenyang economic and Technological Development Zone, Liaoning, China Patentee before: Shenyang Sunshine Pharmaceutical Co.,Ltd. |
|
| CX01 | Expiry of patent term | ||
| CX01 | Expiry of patent term |
Granted publication date: 20060329 |